Sunday, August 09, 2020 9:32:06 PM
Silence.
That's not a question anyone at Anavex will give an answer to. Consider. Any sort of answer, no matter how hazy or lucid, would raise all sorts of complicating issues and contentions of untoward result.
Inasmuch as there have been postings showing putative mechanisms by blarcamesine that would reduce the inflammation of a SARS-CoV-2 infection, or perhaps even obviate such an infection, I have no doubt Anavex has begun to acquire the new strains of rats or mice that are subject to this viral infection. Pretty simple after that. Infect the infection-vulnerable murines, then at various dosages and intervals administer blarcamesine. If nothing happens, discard the idea. But if any of the infected, treated lab rats or mice compare favorably to those who were only infected, blarcamesine will be demonstrated to have efficacy against this virus.
But it would not be wise for the company to reveal any of this. Keep it behind locked lab doors. Then, figure out how to someday run a Phase I safety and tolerability trial on a few dozen humans (perhaps in a nursing home, among a vulnerable population). When that trial is applied for, it will be announced. Nothing before that. Too many erroneous or speculative perceptions.
Some would contend that this posting, itself, would be such. Understood.
Anyone ask IR if they are working on covid19?
That's not a question anyone at Anavex will give an answer to. Consider. Any sort of answer, no matter how hazy or lucid, would raise all sorts of complicating issues and contentions of untoward result.
Inasmuch as there have been postings showing putative mechanisms by blarcamesine that would reduce the inflammation of a SARS-CoV-2 infection, or perhaps even obviate such an infection, I have no doubt Anavex has begun to acquire the new strains of rats or mice that are subject to this viral infection. Pretty simple after that. Infect the infection-vulnerable murines, then at various dosages and intervals administer blarcamesine. If nothing happens, discard the idea. But if any of the infected, treated lab rats or mice compare favorably to those who were only infected, blarcamesine will be demonstrated to have efficacy against this virus.
But it would not be wise for the company to reveal any of this. Keep it behind locked lab doors. Then, figure out how to someday run a Phase I safety and tolerability trial on a few dozen humans (perhaps in a nursing home, among a vulnerable population). When that trial is applied for, it will be announced. Nothing before that. Too many erroneous or speculative perceptions.
Some would contend that this posting, itself, would be such. Understood.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
